89Zr-DFO-MSTP2109A

N/A

Report date: 2025/09/12 17:58:34

Base Information

Drug Name89Zr-DFO-MSTP2109A

Drug Alias NameZirconium89 DFO MSTP2109AZirconium-89 DFO MSTP 2109A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4]

Mechanisms of ActionPositron-emission tomography enhancersAnti-STEAP1

TargetsSix-transmembrane epithelial antigen of the prostate 1

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center Genentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center Genentech Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A